Immunologic, virologic and drug resistance outcomes in an HIV-infected prospective cohort on treatment in South Africa
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0307519 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Bixa Ogola und 4 weiteren Autor:innen. Beteiligte Einrichtung: SAMRC-UNIVEN Antimicrobial Resistance and Global Health Research Unit, HIV/AIDS & Global Health Research Programme, University of Venda, Thohoyandou,…. Hauptthemen laut MEDLINE: HIV Infections, Drug Resistance, Viral, Viral Load, HIV-1. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: South African Medical Research Council, National Research Foundation.
Abstract (Originalsprache)
Background
In September 2016, South Africa introduced the Universal Test and Treat (UTT) programme to manage HIV infection. However, the development of drug resistance and sustaining viral suppression are challenges to the success of treatment programmes. This prospective observational study describes virologic, immunologic, and drug resistance profiles in a test and treat cohort in north-eastern South Africa.
Methods
Five hundred and thirty-four HIV-1 positive antiretroviral naïve adults entering treatment programmes were enrolled between January 2016 and February 2018. Trends in CD4+ cell count, viral load, and drug resistance by examination of deep sequences were assessed at baseline and every three months, for 24 months.
Results
Seventy-five percent were late initiators into ART (that is baseline CD4+ cell counts < 500 cells/microliter) and 16% were early initiators into ART and baseline CD4 was not available for 9%. Eleven percent (12/104) achieved immunological response after 6 months, 39.4% (41 /104) after 12 months, and 97.5% (101/104) after 24 months. Seventy-one percent (381/534) had baseline viral loads >1000 RNA copies/ml. Nine percent (22/246) achieved viral suppression after 3 months, 50% (122/246) after 6 months and 73.6% (181/246) after 12 months. A slower viral suppression was observed for males than females (p value = 0.012). A total of 45.6% (52/114) individuals had at least one drug resistance mutation (DRM) detected at >20% threshold in any of the time points, and the number increased to 55% (63/114) when minor variants were accounted for. Forty-eight percent (14/29) had drug resistance mutations at >5% threshold as early as 3 months into treatment.
Conclusion
The UNAIDS target of 95% viral suppression in individuals under treatment was not observed after 12 months of treatment, and this was less successful for males. Adherence and drug resistance monitoring could be beneficial for individuals harbouring resistant viruses early into treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- SAMRC-UNIVEN Antimicrobial Resistance and Global Health Research Unit, HIV/AIDS & Global Health Research Programme, University of Venda, Thohoyandou, South Africa.
- Discipline of Genetics, School of Life Sciences, University of KwaZulu-Natal, Pietermaritzburg, South Africa.
- Global Biomed Scientific LLC, Forest, VA, United States of America.
- Center for Global Health Equity, University of Virginia, Charlottesville, Virginia, United States of America.
- School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
ORCID-Profile: Bixa Ogola, Nontokozo D Matume, Pascal Obong Bessong
Förderung
- South African Medical Research Council
- National Research Foundation
Zitieren
APA
Ogola, B., Matume, N. D., Tebit, D. M., Mavhandu-Ramarumo, L. G., & Bessong, P. O. (2024). Immunologic, virologic and drug resistance outcomes in an HIV-infected prospective cohort on treatment in South Africa. PLOS ONE. https://doi.org/10.1371/journal.pone.0307519
Vancouver
Ogola B, Matume ND, Tebit DM, Mavhandu-Ramarumo LG, Bessong PO. Immunologic, virologic and drug resistance outcomes in an HIV-infected prospective cohort on treatment in South Africa. PLOS ONE. 2024. doi:10.1371/journal.pone.0307519
BibTeX
@article{Ogola2024,
author = {Ogola, Bixa and Matume, Nontokozo D and Tebit, Denis M and Mavhandu-Ramarumo, Lufuno G and Bessong, Pascal Obong},
title = {Immunologic, virologic and drug resistance outcomes in an HIV-infected prospective cohort on treatment in South Africa},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0307519}
}
EUVIMED